Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rotigotine Schwarz Pharma.

Hermann A M Mucke1

  • 1HM Pharma Consultancy, Enenkelstrasse 28/32, A-1160 Wien, Austria. office@hmpharmacon.com

Idrugs : the Investigational Drugs Journal
|September 10, 2003
PubMed
Summary
This summary is machine-generated.

Rotigotine CDS, a novel transdermal patch, is being developed for Parkinson's disease and restless legs syndrome. This selective dopamine agonist offers a once-daily treatment option.

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patent highlights June - July 2024.

Pharmaceutical patent analyst·2025
Same author

Patent highlights April-May 2024.

Pharmaceutical patent analyst·2025
Same author

Drug Repurposing Patent Applications January-March 2025.

Assay and drug development technologies·2025
Same author

Drug Repurposing Patent Applications October-December 2024.

Assay and drug development technologies·2025
Same author

Patent highlights June - July 2024.

Pharmaceutical patent analyst·2025
Same author

Drug Repurposing Patent Applications July-September 2024.

Assay and drug development technologies·2024
Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010
Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010
Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010
Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010
Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010
Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010
See all related articles

Area of Science:

  • Pharmacology
  • Neurology
  • Drug Delivery Systems

Background:

  • Parkinson's disease and restless legs syndrome are neurological disorders.
  • Dopamine agonists are a key therapeutic class for these conditions.

Purpose of the Study:

  • To evaluate rotigotine CDS, a novel transdermal patch formulation.
  • To assess its potential for treating Parkinson's disease and restless legs syndrome.

Main Methods:

  • Development of a once-daily transdermal patch.
  • Utilizing rotigotine, a naphthol-derived selective D(2) dopamine agonist.

Main Results:

  • Rotigotine CDS is a once-daily transdermal patch formulation.
  • Rotigotine is a selective D(2) dopamine agonist.

Conclusions:

  • Rotigotine CDS shows potential for treating Parkinson's disease.
  • Rotigotine CDS may also be effective for restless legs syndrome.